Medical Command

The Department of the Army Medical Command (MEDCOM), a subordinate command within the U.S. Army responsible for managing the military health system and medical readiness, awards both federal contracts and grants to support clinical training, medical research, health services delivery, and institutional medical operations across Army installations worldwide.

MEDCOM operates a large and active contract portfolio spanning 158,106 awards since 1996, with combined potential value of $40.38 billion. Contract awards have declined significantly over the last five years—from 1,580 awards in 2022 to 86 year-to-date in 2026—reflecting a shift in procurement strategy or consolidation of contracting vehicles. The most recent award closed on October 3, 2026. Prime contractor concentration is highly fragmented; the top five primes by award count hold only 8 percent of recent awards. Goldbelt Frontier, LLC leads by award count with 95 awards and $83.9 million combined potential value, followed by Muscogee Arora JV LLC (54 awards, $38.7 million) and Seva Technical Services, Inc. (39 awards, though potential value is not reported in source data). By potential value, Goldbelt Frontier again ranks first, but Medical Technology Enterprise Consortium enters the top five with 19 awards and $79.6 million in combined potential value—less than 1 percent of MEDCOM's total contract spending. The portfolio reflects substantial contracting through Schedule task orders, BPA calls, or modifications; many high-volume primes carry unreported dollar values. Set-asides are minimal: 82 percent of awards carry no set-aside designation; small business set-asides total 14 percent, with 8(a) sole source at 2 percent and competitive 8(a) at 1 percent.

Recent contract opportunities span medical training, health services, and equipment procurement. MEDCOM is soliciting for human cadaver-based medical training and program support for the 44th Medical Brigade at Fort Bragg (Sources Sought due October 30, 2026); neurocognitive assessment testing support services under Competitive 8(a) for a phase-out modification to an existing IDIQ at Fort Sam Houston (due October 22, 2026); Army Continuing Medical Education reaccreditation consulting services (due October 12, 2026); Athletic Trainer support services for Korea and Europe (due October 6, 2026 for Korea and October 6, 2027 for Europe); hypobaric chamber maintenance at Fort Rucker, Alabama (due October 9, 2026); ground ambulance services at Fort Polk, Louisiana (due October 26, 2026); and standardized predictor and remediation examinations for the U.S. Army Medical Center of Excellence across multiple military medical centers (due September 25, 2026). Several opportunities support overseas medical operations in Europe and Korea. The solicitation pipeline includes both full and open competitions and small-business set-asides.

MEDCOM also administers grant funding for military-relevant medical research. The agency has awarded 3,737 grants since 2006, obligating $4.18 billion in federal dollars. Grant activity has slowed sharply; after 165 awards in 2020 and 232 in 2022, the agency issued only 3 awards in 2025 and 1 award year-to-date in 2026, with the most recent grant award closing on January 5, 2026. The portfolio comprises predominantly Project Grants (90 percent, 3,361 awards) with a smaller Cooperative Agreement share (10 percent, 374 awards). Grant recipient concentration is fragmented; the top five recipients by award count hold 19 percent of recent awards. The University of Texas M.D. Anderson Cancer Center leads by award count with 13 awards and $10.4 million in federal dollars obligated, while Johns Hopkins University ranks first by federal dollars with 7 awards and $11.8 million obligated—together representing less than 1 percent of MEDCOM's total grant obligations. The long tail of 607 distinct recipients indicates a distributed research-funding model.

Current grant opportunities focus on military-relevant clinical and translational research. MEDCOM is funding the Fiscal Year 2026 Breast Cancer Research Program Clinical Research Extension Award (applications due November 18, 2026), supporting research that extends patient follow-up and data analysis in breast cancer clinical studies, and the Breakthrough Award Levels 1 and 2 mechanism (due November 18, 2026), supporting high-impact research on breast cancer with required consumer-advocate participation. The agency also funds the Reconstructive Transplant Research Program Investigator-Initiated Research Award (due November 4, 2026) for studies with military-relevant utility and potential impact on care for service members and veterans recovering from traumatic injury. All grant opportunities are unrestricted in applicant type and support science, technology, and research and development.